Halozyme Therapeutics Q3 Loss Narrows

(RTTNews) - Halozyme Therapeutics, Inc. (HALO) posted third-quarter net loss of $19.3 million or $0.17 per share, narrower than $.0 million or $0.18 per share in the year-ago period.

On average, eight analysts polled by Thomson Reuters expected the company to report a loss of $0.15 per share. Analysts' estimates typically exclude special items.

Operating loss for the quarter narrowed to $18.5 million from $20.0 million in previous year quarter.

Total revenues for the current third quarter soared to $16.01 million from $5.33 million in the comparable quarter last year, while seven analysts had consensus revenue estimate of $14.62 million for the quarter.